Home › Funds › Aureus Asset Management, LLC › ABT

Aureus Asset Management, LLC position in ABT

ABBOTT LABORATORIES · Health Care

Aureus Asset Management, LLC reported holding 343,457 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$33.9M, representing 2.03% of its reported portfolio and ranking #18 among its reported holdings. Aureus Asset Management, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)343.46K sh
Reported value held$33.94M
Portfolio Weight2.03%
First reportedQ3 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Aureus Asset Management, LLC's ABT position evolved

Aureus Asset Management, LLC first disclosed a stake in ABT in Q3 2023 at 66,227 shares (US$6.4M). The position peaked in Q2 2025 at 268,792 shares, worth US$36.6M. Across 13 filings, Aureus Asset Management, LLC increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 343,457 shares valued at US$33.9M — an increase of 29,586 shares quarter over quarter.. Notable position changes include a 334% increase in Q3 2024 (shares were roughly flat over the following quarter), a 25% increase in Q1 2026 (shares fell 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 66.23K $6.41M New
Q4 2023 64.05K $7.05M Reduce
Q1 2024 66.41K $7.55M Add
Q2 2024 62.14K $6.46M Reduce
Q3 2024 269.53K $30.73M Add
Q4 2024 276.21K $31.24M Add
Q1 2025 274.75K $36.45M Reduce
Q2 2025 268.79K $36.56M Reduce
Q3 2025 262.69K $35.18M Reduce
Q4 2025 265.50K $33.26M Add
Q1 2026 331.92K $34.08M Add
Q2 2026 313.87K $28.48M Reduce
Q3 2026 343.46K $33.94M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Aureus Asset Management, LLC held ABT?

Aureus Asset Management, LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Aureus Asset Management, LLC's current position in ABT?

As of Q3 2026, Aureus Asset Management, LLC holds 343.46K shares of ABT (ABBOTT LABORATORIES), valued at $33.94M, representing 2.03% of its reported portfolio and ranking #18.

Has Aureus Asset Management, LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), Aureus Asset Management, LLC increased its position in ABT. The position peaked in Q2 2025 at 268.79K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.